Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
100%(8 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_1
1
9%
Ph phase_4
1
9%
Ph phase_3
5
45%
Ph phase_2
3
27%

Phase Distribution

1

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
5(50.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Not yet recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 23 (30.0%)
Phase 35 (50.0%)
Phase 41 (10.0%)

Trials by Status

completed873%
not_yet_recruiting218%
terminated19%

Recent Activity

0 active trials
Showing 5 of 11
not_yet_recruiting

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

NCT07346547
not_yet_recruitingphase_3

A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

NCT07300111
completedphase_3

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

NCT05682326
completedphase_1

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

NCT04640311
completedphase_4

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

NCT05951192
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07346547

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia

Not Yet Recruiting
NCT07300111Phase 3

A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

Not Yet Recruiting
NCT05682326Phase 3

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

Completed
NCT04640311Phase 1

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

Completed
NCT05951192Phase 4

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Completed
NCT02876835Phase 3

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Completed
NCT03446612Phase 2

Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)

Terminated
NCT03457701Phase 2

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Completed
NCT02879305Phase 3

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Completed
NCT03029208Phase 3

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)

Completed
NCT03029247Phase 2

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11